261 related articles for article (PubMed ID: 25809144)
41. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
42. Extended follow-up of pediatric liver transplantation patients receiving once daily calcineurin inhibitor.
Lin HC; Melin-Aldana H; Mohammad S; Ekong UD; Alonso EM
Pediatr Transplant; 2015 Nov; 19(7):709-15. PubMed ID: 26256288
[TBL] [Abstract][Full Text] [Related]
43. Immunosuppression minimization is safe and associated with good long-term success in pediatric recipients of liver transplant.
Chapin CA; Whitehead B; Shakhin V; Taylor SA; Kriegermeier A; Mohammad S; Alonso EM
Liver Transpl; 2024 Jul; 30(7):707-716. PubMed ID: 37934051
[TBL] [Abstract][Full Text] [Related]
44. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
45. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
46. Is there such a thing as protocol immunosuppression in liver transplantation?
McCaughan GW; Sze KC; Strasser SI
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):1-4. PubMed ID: 25164689
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcome of intensive initial immunosuppression protocol in pediatric deceased donor renal transplantation.
Olaitan OK; Zimmermann JA; Shields WP; Rodriguez-Navas G; Awan A; Mohan P; Little DM; Hickey DP
Pediatr Transplant; 2010 Feb; 14(1):87-92. PubMed ID: 19309452
[TBL] [Abstract][Full Text] [Related]
48. Chronic maintenance immunosuppression in renal transplantation: the unrealized goal of improved long-term outcomes.
Vamenta-Morris H; Keith DS
Minerva Urol Nefrol; 2015 Jun; 67(2):117-38. PubMed ID: 25645345
[TBL] [Abstract][Full Text] [Related]
49. [Nephrology--Part 2. Strategies in the immunosuppression after kidney transplantation].
Sperschneider H; Heemann U; Stein G
Med Klin (Munich); 2003 Mar; 98(3):140-5. PubMed ID: 12647088
[TBL] [Abstract][Full Text] [Related]
50. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
51. Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.
Barbari A; Maawad M; Kfoury Kassouf H; Kamel G
Exp Clin Transplant; 2015 Oct; 13(5):377-86. PubMed ID: 26450460
[TBL] [Abstract][Full Text] [Related]
52. Early steroid withdrawal after renal transplantation.
Colaneri J
Nephrol Nurs J; 2006; 33(1):89-90. PubMed ID: 16538935
[No Abstract] [Full Text] [Related]
53. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
54. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
55. [Low-toxicity immunosuppressive therapy in renal transplant].
Scolari F; La Manna G; Comai G; Cappuccilli ML; Todeschini P; Ciavatti A; Persici E; Feliciangeli G; Stefoni S
G Ital Nefrol; 2007; 24 Suppl 38():44-8. PubMed ID: 17922447
[TBL] [Abstract][Full Text] [Related]
56. The role and value of sirolimus administration in kidney and liver transplantation.
Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
[TBL] [Abstract][Full Text] [Related]
57. The perils of immunosuppression minimization: lessons from protocol biopsies of renal allografts.
Rush DN; Gibson IW
Curr Opin Nephrol Hypertens; 2015 Nov; 24(6):582-6. PubMed ID: 26371528
[TBL] [Abstract][Full Text] [Related]
58. Calcineurin inhibitors in liver transplantation: to be or not to be.
Castroagudín JF; Molina E; Varo E
Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
[TBL] [Abstract][Full Text] [Related]
59. [Minimization or avoidance of calcineurin inhibitors after renal transplantation].
Xue C; Ji ZG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):280-3. PubMed ID: 19621509
[TBL] [Abstract][Full Text] [Related]
60. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
